Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CAM Capital

Investor type Venture Capital
Founders Bruce Kovner


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 22
Average round size
The average size of a deal this fund participated in
Portfolio companies 18
Rounds per year 2.20
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 9
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Biopharma

CAM Capital is the famous VC, which was founded in 2012. The main office of represented VC is situated in the New York. The fund was located in North America if to be more exact in United States.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, Biopharma. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Infinity SDC, Molecular Templates, Antios Therapeutics.

Opposing the other organizations, this CAM Capital works on 34 percentage points more the average amount of lead investments. The increased amount of exits for fund were in 2017. The real fund results show that this VC is 8 percentage points less often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2017.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the CAM Capital, startups are often financed by Third Rock Ventures, Polaris Partners, Lux Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Aisling Capital, Perceptive Advisors. In the next rounds fund is usually obtained by Square 1 Bank, CARB-X.

This organization was formed by Bruce Kovner. Besides them, we counted 1 critical employee of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CAM Capital:
Typical Co-investors
CAM Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CAM Capital:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Kriya Therapeutics

Life Science
$270M16 May 2022 Palo Alto, California, United States


Health Care
$45M05 Jan 2022 Cambridge, Massachusetts, United States

Kriya Therapeutics

Life Science
$100M14 Jul 2021 Palo Alto, California, United States

Health Care
$63M15 Apr 2021 California, United States


Health Care
$115M13 Apr 2021 Maryland, United States

Antios Therapeutics

$96M12 Apr 2021 Atlanta, Georgia, United States

Primmune Therapeutics

Health Care
$27M27 Oct 2020 San Diego, California, United States


$41M09 Oct 2020 Colorado, United States


Health Care
$73M14 Sep 2020 South San Francisco, California, United States
Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.

Arcellx Raises $115M in Series C Financing

– Arcellx Raises $115M in Series C Financing.
– The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners.
– The new investment will be used to develop CART-ddBCMA and initiate clinical trials evaluating ACLX-001 and ACLX-002 in multiple myeloma (MM) and acute myelogenous leukemia (AML) respectively.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CAM Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: